Peripheral Blood Mononuclear Cells Market, By Product Type ( Fresh Peripheral Blood Mononuclear Cells, Cryopreserved Peripheral Blood Mononuclear Cells, Peripheral Blood Mononuclear Cell Isolation & Viability Kits, and Others), By Application ( Human Heme-Oncology PBMCs, Human Breast Cancer PBMCs, Human Rheumatoid Arthritis PBMCs, Human Hepatitis C Virus (HCV) PBMCs, Human Sickle Cell Disease PBMCs, and Others), Industry Trends, Estimation & Forecast, 2014-2026

Check Today's Best Price

$3500 Buy Now
The global Peripheral Blood Mononuclear Cells market is valued at XX million US$ in 2018 is expected to reach XX million US$ by the end of 2026, growing at a CAGR of XX % during 2019-2026
  • Market Overview

    The global Peripheral Blood Mononuclear Cells market is valued at XX million US$ in 2018 is expected to reach XX million US$ by the end of 2026, growing at a CAGR of XX % during 2019-2026.

    Peripheral Blood Mononuclear Cells (PBMC), are also known as Human Mononuclear Cells from Peripheral Blood (HMNC-PB), which are widely used in research and clinical applications, and provide a useful tool for studying various aspects of pathology and biology in vitro. Cell Applications PBMC are cryopreserved immediately after isolation. Peripheral Blood Mononuclear Cells (PBMC), consist of lymphocytes and monocytes. In humans, lymphocytes make up the majority of the PBMC population, followed by monocytes, and only a small percentage of dendritic cells. Scientists are researching in the fields of immunology, infectious disease, hematological malignancies, vaccine development, transplant immunology, and high-throughput screening use PBMCs. In many cases, PBMCs are derived from blood banks.

    Peripheral Blood Mononuclear Cells Market value-2016-2026

    Market Driver

    The increasing use of Peripheral Blood Mononuclear Cells (PBMC) for research and clinical studies is boosting the global Peripheral Blood Mononuclear Cells market.

    Peripheral Blood Mononuclear Cells are important tools for studies in Immunology infectious disease, hematological malignancies, vaccine development, transplant immunology, high-throughput screening, and Neovascularization. It helps to improve limb ischemia and in cell therapy to repair ischemic and infracted myocardium, Human body defense mechanisms critical in the immune system to fight bacterial and viral infections, and function as immune surveillance network to kill tumor cells. It is also used for the secretion of cytokines to regulate immune response and inflammation. PBMCs, as a model system, has been widely used to study metabolic and autoimmune diseases.

    Prostate cancer is the second leading cause of cancer deaths in men globally, the use of Peripheral Blood Mononuclear Cells for Prostate Cancer Studies. For example, in 2010, the FDA approved the first autologous cellular immunotherapy drug for treating patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The drug, known as sipuleucel-T, is manufactured via a unique process that activates PBMCs with a fusion protein. This study looked at a larger sample of data from three phase 3 trials to gain a greater understanding of how the therapy engages the immune system via PBMC activation.

    Market Restraint

    Lack of research practices in developing nations is a major drawback hampering the global Peripheral Blood Mononuclear Cells market. As the developing countries have insufficient resources or a weak infrastructure to support their research. The Global Forum for Health Research reports that only 10% of research funding is spent on 90% of the world’s health problems, therefore using funds from developed countries to address health disparities in the lesser developed countries.

    Segment Analysis

    Based on product type, the global Peripheral Blood Mononuclear Cells market is broadly segmented as Fresh Peripheral Blood Mononuclear Cells, Cryopreserved Peripheral Blood Mononuclear Cells, Peripheral Blood Mononuclear Cell Isolation & Viability Kits, and Others. In 2018 Cryopreserved Peripheral Blood Mononuclear Cells is the dominant segment, and it accounts for approximately XX% of the market.

    Cryopreserved peripheral blood mononuclear cells are useful in clinical trials that have low end-point frequencies because they allow the immunologic assays to be performed after the conclusion of the studies when all the endpoints have already been identified. PBMCs possess stable viability and function over prolonged periods when adequately stored, and can be used in substitution of fresh PBMCs for several phenotypic and functional assays.

    The use of cryopreserved peripheral blood mononuclear cells (PBMC) for immunologic assays has intensely increased in recent years. Cryopreserved PBMC are particularly useful in clinical trials with low end-point frequencies because they allow the immunologic assays to be performed after the conclusion of the studies when all the endpoints have already been identified. Additionally, the use of cryopreserved PBMC allows all assays to be performed in a single laboratory, eliminating interlaboratory variability, which has been a confounder in some studies. The availability of cryopreserved peripheral blood mononuclear cells (PBMC) in the market is boosting the global peripheral blood mononuclear cells market. For instance, on September 20, 2018, StemExpress, a Folsom, California based leading supplier of human biospecimens, have introduced frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications, such as cancer, autoimmune diseases, device development, and other applications.

    Regional Analysis

    The global Peripheral Blood Mononuclear Cells market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

    North America is dominating the global Peripheral Blood Mononuclear Cells market, due to the increasing capacity for peripheral blood mononuclear cell (PBMC) storage. For instance, May 23, 2018, LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, has completed phase one of an 11,000+ square foot facility expansion in Johnson City, Tennessee. The new space will increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to serve its clients better. It is estimated that the phase three will be finished soon for better clinical studies

    The North America Peripheral Blood Mononuclear Cells market size was XX million USD in 2018, and it will be XXX million USD in 2026, with a CAGR XX% from 2019 to 2026.

    Europe has shown significant growth in 2018, due to the introduction of new product in the market. For instance, June 14, 2017, Miltenyi Biotec, has introduced the new MACSprep PBMC Isolation Kit, that allows the preparation of highly pure peripheral blood mononuclear cells (PBMCs) from whole human blood without density gradient centrifugation in only 25 min. The kit is ideal for the processing of small blood samples.

    Competitive Analysis

    The major players include BioIVT, Biovision, Atzlabs, Creative Bioarray, CELL Applicaton, Inc., Miltenyl Biotec, Precision Medicine Group, and others

    The implementation of peripheral blood mononuclear cells (PBMC) in the research study is boosting the global Peripheral Blood Mononuclear Cells market. For instance, September 5, 2018, SGS, a life sciences, pharmaceutical, clinical and bioanalytical contract solutions provider, has successfully executed advanced techniques for the collection and use of peripheral blood mononuclear cells (PBMCs) for early phase clinical trials at its clinical pharmacology unit (CPU) in Antwerp, Belgium, and is also further strengthening its offer in the areas of infectious disease therapeutics and vaccines. PBMCs are already widely used to study various aspects of pathology and biology in vitro but are also used in clinical studies in, as well as infectious diseases, hematological malignancies, vaccine development, and transplant immunology.

    Global Peripheral Blood Mononuclear Cells Market

    • Consumption by Regions
      • North America
      • Europe
      • China
      • Japan
      • Rest of the World
    • Segment by Product Type
      • Fresh Peripheral Blood Mononuclear Cells
      • Cryopreserved Peripheral Blood Mononuclear Cells
      • Peripheral Blood Mononuclear Cell Isolation & Viability Kits
      • Others
    • Segment by Application
      • Human Heme-Oncology PBMCs
      • Human Breast Cancer PBMCs
      • Human Rheumatoid Arthritis PBMCs
      • Human Hepatitis C Virus (HCV) PBMCs
      • Human Sickle Cell Disease PBMCs
      • Others
    keyboard_arrow_up
  • Table of Contents

    1 Introduction
    1.1 Executive Summary
    1.2 Market Definition
    1.3 Market Scope

    2 Research Methodology
    2.1 Primary Research
    2.2 Research Methodology
    2.3 Assumptions & Exclusions
    2.4 Secondary data sources

    3 Market Overview
    3.1 Report Segmentation & Scope
    3.2 Key Market Trends
    3.2.1 Drivers
    3.2.1.1 Increasing research in cell biology in industrialized economies
    3.2.1.2 Increasing application of PBMCs in the various disease area
    3.2.2 Restraints
    3.2.2.1 Preservation, storage and transportation limitations
    3.2.2.2 Lack of research practices in developing nations
    3.2.3 Opportunities
    3.3 Porter’s Five Forces Analysis
    3.3.1 Porter’s Five Forces Analysis
    3.4 Market Share Analysis

    4 Product Overview
    4.1 Introduction
    4.1.1 Market Size & Forecast
    4.2 Fresh Peripheral Blood Mononuclear Cells
    4.2.1 Market Size & Forecast
    4.3 Cryopreserved Peripheral Blood Mononuclear Cells
    4.3.1 Market Size & Forecast
    4.4 Peripheral Blood Mononuclear Cell Isolation & Viability Kits
    4.4.1 Market Size & Forecast
    4.5 Others
    4.5.1 Market Size & Forecast

    5 Type Overview
    5.1 Introduction
    5.1.1 Market Size & Forecast
    5.2 Human Heme-Oncology PBMCs
    5.2.1 Market Size & Forecast
    5.3 Human Breast Cancer PBMCs
    5.3.1 Market Size & Forecast
    5.4 Human Rheumatoid Arthritis PBMCs
    5.4.1 Market Size & Forecast
    5.5 Human Hepatitis C Virus (HCV) PBMCs
    5.5.1 Market Size & Forecast
    5.6 Human Sickle Cell Disease PBMCs
    5.6.1 Market Size & Forecast
    5.7 Others
    5.7.1 Market Size & Forecast

    6 Regional Overview
    6.1 Introduction
    6.1.1 Market Size & Forecast
    6.2 North America
    6.2.1 Market Size & Forecast
    6.2.2 North America Market Size & Forecast, By Country
    6.2.3 North America Market Size & Forecast, By Product
    6.2.4 North America Market Size & Forecast, By Type
    6.2.5 U.S.
    6.2.5.1 Market Size and Forecast
    6.2.6 Canada
    6.2.6.1 Market Size and Forecast
    6.2.7 Mexico
    6.2.7.1 Market Size and Forecast
    6.3 Europe
    6.3.1 Market Size & Forecast
    6.3.2 Europe Market Size & Forecast, By Country
    6.3.3 Europe Market Size & Forecast, By Product
    6.3.4 Europe Market Size & Forecast, By Type
    6.3.5 Germany
    6.3.5.1 Market Size and Forecast
    6.3.6 France
    6.3.6.1 Market Size and Forecast
    6.3.7 UK
    6.3.7.1 Market Size and Forecast
    6.3.8 Italy
    6.3.8.1 Market Size and Forecast
    6.3.9 Spain
    6.3.9.1 Market Size and Forecast
    6.3.10 Rest of Europe
    6.3.10.1 Market Size and Forecast
    6.4 Asia-Pacific
    6.4.1 Market Size & Forecast
    6.4.2 Asia-Pacific Market Size & Forecast, By Country
    6.4.3 Asia-Pacific Market Size & Forecast, By Product
    6.4.4 Asia-Pacific Market Size & Forecast, By Type
    6.4.5 Japan
    6.4.5.1 Market Size and Forecast
    6.4.6 China
    6.4.6.1 Market Size and Forecast
    6.4.7 Australia
    6.4.7.1 Market Size and Forecast
    6.4.8 India
    6.4.8.1 Market Size and Forecast
    6.4.9 South Korea
    6.4.9.1 Market Size and Forecast
    6.4.10 Rest of Asia-Pacific
    6.4.10.1 Market Size and Forecast
    6.5 Rest of the World
    6.5.1 Market Size & Forecast
    6.5.2 Rest of the World Market Size & Forecast, By Country
    6.5.3 Rest of the World Market Size & Forecast, By Product
    6.5.4 Rest of the World Market Size & Forecast, By Type
    6.5.5 South America
    6.5.5.1 Market Size and Forecast
    6.5.6 Middle East
    6.5.6.1 Market Size and Forecast
    6.5.7 Africa
    6.5.7.1 Market Size and Forecast

    7 Company Profile
    7.1 BioIVT
    7.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Its Competitors
    7.1.2 BioIVT Product Category, Application, and Specification
    7.1.2.1 Product A
    7.1.2.2 Product B
    7.1.3 BioIVT Financial Performance (2016-2018)
    7.1.4 Main Business/Business Overview
    7.2 Biovision
    7.3 Atzlabs
    7.4 Creative Bioarray
    7.5 CELL Application, Inc
    7.6 Miltenyl Biotec
    7.7 Precision Medicine Group

    keyboard_arrow_up
    • The following manufacturers are covered:
      • BioIVT
      • Biovision
      • Atzlabs
      • Creative Bioarray
      • CELL Applicaton, Inc.
      • Miltenyl Biotec
      • Precision Medicine Group
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS